Poly Pharmaceutical Obtains Market Approval for Azithromycin Injection in Israel, Further Securing Antibiotic Supply
Poly Pharmaceutical Co., Ltd. (hereinafter referred to as "Poly Pharmaceutical") recently received market approval from the Israeli Ministry of Health's Pharmacy Division for the sale of Azithromycin injection. This signifies that Poly Pharmaceutical's production of Azithromycin injection is eligible for sale in the Israeli market.
Previously, Bivalirudin injection and Ganciclovir injection of Poly Pharmaceutical had already obtained market approval in Israel in January and July 2023, respectively.
The successive market approvals will have a positive impact for Poly Pharmaceutical on the expansion of the Israeli market.
In the future, the company will continue to implement its strategy of exporting high-quality pharmaceutical products. For more information on other pharmaceutical products that are currently under export application to Israel, please refer to the table I below:
Table 1 List of Poly Pharmaceutical’s Product being Declared for Export to Israel
Product Name | Country to be Declared | Expected Date of Approval | Current State |
Pantoprazole Sodium Injection (40mg) | Israel | 2025.06 | Under Review |
Daptomycin Injection (500mg) | Israel | 2025.12 | Under Review |
Azithromycin Injection (500mg) | Israel | 2025.12 | Under Review |
Voriconazole Injection (200mg) | Israel | 2025.12 | Under Review |
Eptifibatide Injection (20mg/10mg) | Israel | 2025.12 | Under Review |
Azithromycin OverviewThe compound Azithromycin, initially developed by the Pliva research team, was discovered and formulated. In 1986, Pliva signed an authorization agreement with Pfizer, granting Pfizer exclusive marketing rights in Western Europe and the United States. In 1997, Pfizer's Azithromycin injection (marketed as ZITHROMAX) received approval for sale in the United States, and in 2007, the original formulation (marketed as ZITHROMAX) was approved for sale domestically. Azithromycin injection is currently widely available and used globally, primarily for upper and lower respiratory tract infections, skin and soft tissue infections, and is classified as a broad-spectrum macrolide antibiotic.
Israel's Advanced Healthcare System and High Medical Demand
Israel, situated in Western Asia, is the only developed country in the Middle East and one of four developed nations in Asia, with a per capita GDP reaching $54,600 in 2022, ranking 16th globally, and a total population of 9.59 million people.
Israel's medical standards enjoy international acclaim, medical conditions are comparable to North America and Western Europe, and medical demand is high.
Antibiotics are crucial life-saving medications and strategic resources. The approval of Poly Pharmaceutical's Azithromycin injection will further ensure the supply of these essential medications in Israel.
-
[Previous]Anhui Poly Pharmaceutical's Magnesium Hydroxide API Approved for Market, with a Yearly Production Capacity of Up to 200 Tons!
-
[Next]Hainan Poly Pharmaceuticals’ Injection and Raw Material Workshops Receive US FDA Certification Again!
Home